Results 41 to 50 of about 61,179 (292)

Allopurinol reduces antigen-specific and polyclonal activation of human T cells

open access: yesFrontiers in Immunology, 2012
Allopurinol is the most popular commercially available xanthine oxidase inhibitor and it is widely used for treatment of symptomatic hyperuricaemia, or gout. Although, several anti-inflammatory actions of allopurinol have been demonstrated in vivo and in
Damián ePérez-Mazliah   +7 more
doaj   +1 more source

Prevention effect of allopurinol on post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of prospective randomized controlled trials. [PDF]

open access: yesPLoS ONE, 2014
BACKGROUND: Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP) which can be severe and cause death in approximately 10% of cases.
Wei-Li Cao   +4 more
doaj   +1 more source

Acute kidney injury in critically ill cancer patients : an update [PDF]

open access: yes, 2016
Patients with cancer represent a growing group among actual ICU admissions (up to 20 %). Due to their increased susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment, these patients ...
Benoit, Dominique   +3 more
core   +2 more sources

Comparative Study of Allopurinol and Uralyt-4 in patients with Hyperuricemia in Diyala Governorate.

open access: yesمجلة كلية الطب, 2014
Background: Hyperuricemia represents a major public health problem; approximately most population has hyperuricemia, serum uric acid ≥6.5 mg/dL in women and ≥7.0 mg/dL in men.
Zuhir M. Hussein   +2 more
doaj   +1 more source

Effects of Allopurinol as a xanthine oxidase inhibitor on depressive-like behavior of rats and changes in serum BDNF level

open access: yesIBRO Neuroscience Reports, 2022
Background: Depression is a psychiatric disorder characterized by low mood and loss of interest in daily activities. Allopurinol, a xanthine oxidase blocker, is widely administered for the treatment of hyperuricemia.
Mahsa Hadipour Jahromy   +2 more
doaj   +1 more source

Solubility and Permeability Improvement of Allopurinol by Cocrystallization

open access: yesCrystal Growth & Design, 2020
Allopurinol is a xanthine oxidase inhibitor with poor solubility and permeability, which severely limit its drug absorption following the administration of some dosage forms, such as tablets and re...
Xia-Lin Dai   +6 more
semanticscholar   +1 more source

How to improve drug dosing for patients with renal impairment in primary care - a cluster-randomized controlled trial [PDF]

open access: yes, 2012
Background: Patients with chronic kidney disease (CKD) are at increased risk for inappropriate or potentially harmful prescribing. The aim of this study was to examine whether a multifaceted intervention including the use of a software programme for the ...
Beyer, Martin   +7 more
core   +1 more source

Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell function [PDF]

open access: yes, 2014
Xanthine oxidase (XOD) is an enzyme which plays a central role in purine catabolism by converting hypoxanthine into xanthine and then further into uric acid.
Abooali, Maryam   +5 more
core   +1 more source

Allopurinol-Induced Stevens–Johnson Syndrome in Javanese Men With Positive HLA‐B*58:01

open access: yesFrontiers in Genetics, 2022
Background: Allopurinol is the most commonly used drug for the treatment of gout arthritis. However, the use of allopurinol is associated with severe cutaneous adverse reactions (SCARs) and life-threatening immune-mediated reactions that include Stevens ...
Astri Ferdiana   +8 more
doaj   +1 more source

Pharmacology and clinical drug candidates in redox medicine [PDF]

open access: yes, 2015
SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I   +11 more
core   +3 more sources

Home - About - Disclaimer - Privacy